BEIJING (Reuters) – A city in China is offering Synovac Biotech’s experimental COVID-19 vaccine to essential activists and other high-risk groups as part of a national program for about $ 60.
The eastern city of Jiaxing’s Center for Disease Control and Prevention (CDC) said in a statement on WeChat that two doses of a vaccine candidate named Coronavac, 200 yuan ($ 29.75) per dose, and the vaccination of key groups, including medical professionals, would cost. started.
Chinese authorities do not have to release pricing details for potential COVID-19 vaccines. Hundreds of thousands of people have been given experimental vaccines in late-stage trials as part of an emergency vaccination program launched in July.
It was unclear if subsidies are also included in the pricing of Jiaxing City. The city’s CDC declined to comment.
Synovac did not immediately respond to a request for comment. Its vaccine is in late-stage trials in Brazil, Indonesia and Turkey, and the company said an interim analysis of Phase 3 trial data could come in early November.
Bio Pharma, a state-owned company in Indonesia that reached a deal for at least 40 million from Synovac, said the vaccine would cost around 200,000 rupees ($ 13.60) per dose this week, when it went south. Will be available in the East Asian country.
China has stated that while fair benefits are allowed for companies, COVID-19 vaccines should be close to cost.
The China National Pharmaceutical Group (Sinopharm) said in August that a vaccine candidate developed by a unit could cost no more than 1,000 yuan ($ 148.80) for two shots. An official of China’s National Health Commission has said, however, the price will be lower.
($ 1 = 6.7220 Chinese Yuan)
($ 1 = Rs. 14,690.0000)
(Reporting by Roxanne Liu and Tony Munro in Beijing. Additional reporting by Kate Lamb; Editing by Sayantani Ghosh and Edwina Gibbs)